VB-111 in Surgically Accessible Recurrent/Progressive GBM
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This research study is studying a new viral cancer therapy, ofranergene obadenovec (VB-111),
for recurrent or progressive glioblastoma (GBM), a brain tumor that is growing or progressing
despite earlier treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Vascular Biogenics Ltd. operating as VBL Therapeutics